Background: There is ample evidence associating vitamin D deficiency in primary hyperparathyroidism (PHP) patients with more severe disease manifestations and increased risk of postoperative hypocalcemia. Yet, there is limited data regarding the safety of vitamin D repletion in these patients. Aim: To assess the safety of vitamin D repletion in PHP patients in a real-world setting. Design: We included patients with asymptomatic PHP and few symptomatic patients who declined surgery, followed in our clinic, and treated on a routine basis with 2000 IU/day of vitamin D 3 . Methods: Serum calcium (sCa), PTH, 25-hydroxyvitamin D, and 24 h urinary calcium (uCa) and creatinine collections were compared between the lowest and the highest vitamin D time points. Results: There were 40 patients of a mean age was 63 6 10 years. 25(OH)D at lowest and highest vitamin D time points was 15.5 6 6.2 ng/ml and 33.2 6 8, respectively (P < 0.001). Serum calcium was not affected by the changes in vitamin D levels. In none of the patients did sCa exceed 11.5 mg/dL. uCa was 220 6 110 mg/24 h at the lowest vitamin D time point and 260 6 140 at the highest vitamin D time point (P ¼ 0.14). uCa exceeded 400 mg/24 h in two vs. five patients (P ¼ 0.23) at the lowest and highest vitamin D time points, respectively. PTH was not significantly different between the different vitamin D time points. Discussion/Conclusion: Vitamin D repletion in PHP seems safe. Considering the documented adverse influence of vitamin D deficiency in PHP, particularly on skeletal manifestations and on the postoperative course, vitamin D repletion is warranted.
Introduction
Primary hyperparathyroidism (PHP) and vitamin D deficiency are interconnected on several levels. Epidemiological studies indicate that even within vitamin D sufficient populations, vitamin D deficiency is more prevalent in PHP patients than in matched controls. 1, 2 Clinical and pathological manifestations of PHP are more prominent in vitamin D deficient patients. 3 The severity of the clinical, biochemical and pathological manifestations of PHP are much more prominent in world regions endemic for vitamin D deficiency, reflected in higher serum calcium, alkaline phosphatase and high rates of brown tumors, pathological fractures, renal stones and nephrocalcinosis. 4 Even in developed countries, an inverse correlation was observed between serum calcium and 25(OH)D concentrations 5 and vitamin D deficiency may, in some cases, obscure the hypercalcemia of PHP, which may increase and becomes evident following vitamin D repletion. 6 Consequently, vitamin D-based nomograms have been designed to refine the diagnosis of PHP diagnosis in vitamin D-deficient patients. 5, 7 In vitamin D deficient patients, parathyroid hormone (PTH) concentrations are higher and inversely correlated with the degree of vitamin D deficiency 3, 8 and parathyroid adenomas tend to be larger. 9 Bone histomorphometric studies revealed cortical bone thinning along with widening of bone trabecules in vitamin D-deficient PHP patients, while no differences were observed in parameters of bone remodeling. 8 Bone mineral density (BMD) is lower in vitamin D deficient, compared to vitamin D-replete PHP patients. 2, 3, 8, 10 Finally, the risk of hypocalcaemia following parathyroidectomy is considerably increased in vitamin D deficient patients. 11, 12 Limited data exist regarding the outcome of vitamin D repletion in vitamin D-deficient patients with PHP. [13] [14] [15] The present study was aimed to examine the influence of vitamin D normalization on parameters of calcium metabolism in vitamin D deficient patients with PHP in a real-world setting.
Materials and methods
The study was performed at the endocrine clinic of the Hillel Yafe Medical Center, Hadera, Israel.
We retrospectively examined electronic medical records of PHP patients who attended our clinic between 2005 and 2009 . The study included 38 patients with asymptomatic hypercalcemic PHP and 2 with symptomatic PHP (both with a history of renal calculi) who declined surgery. All patients had normal renal function. Patients with normocalcemic hyperparathyroidism, patients with only one measurement of 25(OH)D and those with increment of serum 25(OHD) of less than 5 ng/ml were not included in the study. All PHP patients were treated on a routine basis with 2000 IU/day of vitamin D 3 and were encouraged to enrich their nutritional calcium intake to between 800 and1000 mg/day. Continuous variables with normal distribution are presented as mean 6 SD and were compared by paired t-test. Parametric variables were compared by v 2 test.
The study protocol was approved by the Human-research Ethics Board, Hillel Yaffe Medical Center, Hadera, Israel.
Results
The demographic and clinical characteristics of the study patients are presented in Table 1 . There were 40 patients, 34 women and 6 men, who met the inclusion criteria. Biochemical parameters are presented in Table 2 . The mean age (6 SD) was 63 6 10.5 years (range: 39-88). The mean (6 SD) serum calcium was 10.7 6 0.4 mg/dL. Table 1 ). The mean 25(OH)D at the lowest point was 15.5 6 6.2 ng/ml and 33.2 6 8 ng/ml at the highest point (P < 0.001). The mean difference in serum calcium at the respective lowest and highest points was 0.0 6 0.36 mg/dL (range: À0.8 to 0.8). In none of the patients did the serum calcium exceed 11.5 mg/dL. Urinary calcium excretion was 220 6 110 mg/24 h at the lowest vitamin D point and 260 6140 at the highest vitamin D point (P ¼ 0.14). Mean change difference was 31 6 159 mg/24 h (range: 366-427). Urinary calcium exceeded 400 mg/24 h in two patients at the lowest vitamin D time point and in five patients at the highest time point (P ¼ 0.23; v 2 test). PTH was 128 6 42 pg/ml at the lowest vitamin D point and 132 6 52 pg/ml at the highest point, which was not statistically significant. 
Discussion
Our results indicate that in a population of PHP patients with mild to moderate vitamin D deficiency, supplementation with 2000 IU/day of vitamin D 3 is generally safe. Serum calcium remained stable and did not exceed 11.5 mg/dl in any of our patients. There were very few, mild, subclinical, adverse events, particularly hypercalciuria (>400 mg/24 h), in 12% of our patients. Unfortunately, despite that patients were encouraged to increase their nutritional calcium intake, we could not obtain Finally, a documented association between PHP and overweight could also contribute to vitamin D deficiency in these patients.
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Our results add to a modest body of previous studies, focused on clarifying safety issues associated with vitamin D replenishment in PHPT patients. The studies were mostly observational and retrospective, similar to the present study, with a total of about 300 PHP patients with mostly mild, asymptomatic disease, with a total serum calcium concentration usually not exceeding 10.8 mg/dL. 13 32 Follow-up ranged from 1 month to more than 1.5 years. Vitamin D deficiency in all those studies was mild to moderate with a mean basal serum 25(OH)D ranging between 5.9 and 18 ng/ml, increased significantly to between 28 and 106 ng/ml, well above the >30 ng/ml, vitamin sufficient range, in most of the patients. Overall, the various studies, as well as our own, revealed no clinically significant change in the mean total serum calcium concentrations following vitamin D repletion. PTH remained stable, as in the present study, 30, 32, 33 or slightly decreased. 13, 14, 31, 34 Adverse effects were uncommon and asymptomatic, reflected by excessive increase in total serum calcium up to 11.7 mg/dL. 14, 32, 33 Asymptomatic increase in total serum calcium above 12 mg/dL and up to 12.4 mg/dL was reported by Tucci et al. in 3 (5%) of their patients. 15 Rathi et al. reported increase in urinary calcium excretion >400 mg/24 h in 33% of the patients at 12 months, which decreased to basal levels upon decrease in dose or withdrawal of vitamin D 3 treatment. 31 In our own study there were twice as many patients with urinary calcium excretion >400 mg/24 at the highest vitamin D time point compared to the lowest time point (12.5% vs. 5%), which did not reach statistical significance. and 24 h urinary excretion remained stable, and no drug-related clinical adverse events were noted. Much of the available data on vitamin D replenishment in PHP patients has been recently meta-analyzed by Shah et al., 36 concluding that vitamin D treatment is generally safe and not associated with hypercalcemia or hypercalciuria.
As for possible beneficial effects of vitamin D replenishment in PHP patients, available data suggest that vitamin D replenishment could be associated with improvement in spine BMD, 18, 37 possibly in hip, 37 but not in distal radius BMD. 18 A concurrent decrease in bone turnover markers, CTX and P1NP, was also observed in vitamin D treated patients, of which only CTX reached statistical significance. 18 In addition, vitamin D repletion could reduce the postoperative hypocalcemic events following parathyroidectomy.
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Conclusion
Despite a recent study noting that low vitamin D levels have become less common in primary hyperparathyroidism patients, 38 vitamin D insufficiency an deficiency are still frequently encountered in real-world practice. Vitamin D deficiency in patients with PHP is associated with more severe disease manifestations. Available data indicate that in patients with a mild to moderate PHP, as are most of the currently attended patients in Western countries, vitamin D supplementation is associated with no clinical adverse effects and rarely with some increase in total serum calcium or hypercalciuria, which can be managed through adjustment of the vitamin D dose. We are not aware of data regarding the safety of pre-operative vitamin supplementation in patients with severely hypercalcemic PHP or with extreme vitamin D deficiency. A more prudent surveillance is mandatory in such cases. 
